Thread by @WHO

COVAX has agreements in place to access nearly 2 billion doses of several promising #COVID19 vaccine candidates, and has laid the groundwork for further doses to be secured through contributions from donors bit.ly/3muPRtp

All COVAX’s 190 participating and eligible economies will be able to access vaccine doses to protect vulnerable groups in the first half of 2021. bit.ly/3muPRtp #COVID19

https://twitter.com/WHO/status/1339965611376582659?s=20

At least 1.3 billion donor-funded #COVID19 vaccine doses will be made available to 92 economies eligible for the @gavi COVAX Advance Market Commitment, targeting up to 20% population coverage by the end of the year. bit.ly/3muPRtp

The new deals include:
Advance purchase agreement with AstraZeneca for 170M doses of the AstraZeneca/Oxford candidate vaccine
Memorandum of understanding with Johnson & Johnson for 500M doses of the Janssen candidate, which is currently being investigated as a single dose vaccine

The new deals are in addition to existing agreements with:
-the Serum Institute of India for 200M doses – with options for up to 900M doses more of either the AstraZeneca/Oxford or Novavax candidates
-the Sanofi/GSK for 200M doses

#COVID19

https://twitter.com/WHO/status/1339966196758753281?s=20

COVAX also has first right of refusal in 2021 to access potentially more than one billion doses of candidates in the COVAX R&D vaccine Portfolio.
bit.ly/3muPRtp #COVID19

Funding raised in 2020 and early pledges toward 2021 targets, with these agreements, offer clearest pathway yet to end the acute phase of the #COVID19 pandemic globally by the end of 2021. bit.ly/3muPRtp

The COVAX Facility has opened another potential source of vaccines: the Principles for Dose-Sharing, which provides a framework for higher-income economies to make additional volumes secured via bilateral deals available through the Facility on an equitable basis.